Suggested remit: To appraise the clinical and cost effectiveness of benralizumab with corticosteroids within its marketing authorisation for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6266

Provisional Schedule

Expected publication 16 July 2025

Project Team

Project lead Vonda Murray

Email enquiries

External Assessment Group Newcastle NIHR TAR Team, Newcastle University

Stakeholders

Companies sponsors AstraZeneca
Others Department of Health and Social Care
  NHS England
  Health Technology Wales
Patient carer groups Asthma + Lung UK
  Cardiac Risk in the Young
  EOS Network
  Genetic Alliance UK
  Kidney Care UK
  Kidney Research UK
  Lauren Currie Twilight Foundation
  Lupus UK
  National Kidney Federation
  National Rheumatoid Arthritis Society
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Vasculitis UK
  Versus Arthritis
Professional groups Association for Respiratory Technology and Physiology
  Association of Respiratory Nurse Specialists
  British Association for Paediatric Nephrology
  British Association of Dermatologists
  British Association of Urological Nurses
  British Association of Urological Surgeons
  British Dermatological Nursing Group
  British Geriatrics Society
  British Society for Paediatric and Adolescent Rheumatology
  British Society for Rheumatology
  British Thoracic Society
  Health Lumen
  Immunodeficiency UK
  Primary Care Dermatology Society
  Primary Care Respiratory Society UK
  Primary Care Rheumatology and Musculoskeletal Medicine Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for DGH Nephrologists
  Society of Vascular Nurses
  UK Clinical Pharmacy Association
  UK Kidney Association
  UK Renal Pharmacy Group
  Urology Foundation
Assessment group Newcastle NIHR TAR Team, Newcastle University
Associated guideline groups NICE - National Guideline Centre
  National Institute for Health and Care Excellence
Associated public health groups Public Health Wales
  UK Health Security Agency
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Hospital Information Services – Jehovah’s Witnesses
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups British Society for Dermatological Surgery
  British Skin Foundation
  Dermatrust
  Cochrane Skin Group
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research
  Skin Treatment and Research Trust
  UK and Ireland Vasculitis Rare Disease Group

Timeline

Key events during the development of the guidance:

Date Update
30 September 2024 Invitation to participate
16 July 2024 - 13 August 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6266
16 July 2024 In progress. Scoping commencing
17 May 2024 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late September 2024 when we will write to you about how you can get involved.
18 January 2024 Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.
18 January 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual